Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "ITU"

2208 News Found

Cipla Health launches Astaberry's campaign 'Get the Rich Look'
News | July 17, 2025

Cipla Health launches Astaberry's campaign 'Get the Rich Look'

The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.


Syngene announces 3rd year of STEM scholarship for women with RICH
News | July 11, 2025

Syngene announces 3rd year of STEM scholarship for women with RICH

This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background


Merck KGaA bestows 2025 Future Insight Prize to Helmholtz Center’s Magdalena Gotz for breakthroughs in brain regeneration
People | July 09, 2025

Merck KGaA bestows 2025 Future Insight Prize to Helmholtz Center’s Magdalena Gotz for breakthroughs in brain regeneration

Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich


BioMed X and Servier launch AI-powered antibody research at New XSeed Labs in Paris-Saclay
News | July 09, 2025

BioMed X and Servier launch AI-powered antibody research at New XSeed Labs in Paris-Saclay

The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies


Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
Policy | July 07, 2025

Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB

CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders


Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO
People | July 07, 2025

Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO

Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries


Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer
Clinical Trials | July 06, 2025

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone


Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy
News | July 03, 2025

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008